

01/12/2016



**3rd ESH INTERNATIONAL CONFERENCE ON
NEW CONCEPTS IN LYMPHOID MALIGNANCIES:
Focus on CLL and Indolent Lymphoma**

Mandelieu Congress Center, Mandelieu, France
September 15-17, 2017

Chairs: Michael Hallek, Stephan Stilgenbauer, Louis Staudt, Andrei Thomas-Tikhonenko

Friday, September 15, 2017

08:00–08:15 Welcome

SESSION I – BIOLOGY 1

Chair: TBA

- 08:15-08:35 Pathways of B-cell differentiation and lymphoid cancer Jason Cyster (San Francisco)*
- 08:35-08:40 *Discussion*
- 08:40-09:00 Genomic landscape of CLL and other indolent lymphoma Cathy Wu (Boston)
09:00-09:05 *Discussion*
- 09:05-09:25 Routes of transformation of follicular lymphoma Jude Fitzgibbon (London)
09:25-09:30 *Discussion*
- 09:30-09:50 Mechanism of lymphoma progression Riccardo Dalla-Favera (New York)
09:50-09:55 *Discussion*
- 09:55-10:25 ***Oral presentations selected from submitted abstracts and/or Round table or controversial debates***

10:25-11:00 Coffee Break

SESSION II – BIOLOGY 2

Chair: TBA

- 11:00-11:20 B Cell-receptor signaling Michael Reth (Freiburg)*
11:20-11:25 *Discussion*
- 11:25-11:45 CLL microenvironment as a drug target for kinase inhibitors Jan Burger (Houston)
11:45-11:50 *Discussion*
- 11:50-12:10 Mechanisms of BCR signaling in lymphoma Louis Staudt (Bethesda)
12:10-12:15 *Discussion*
- 12:15-12:35 Modulation of the TME in NHL Adrian Wiestner (Bethesda)
12:35-12:40 *Discussion*
- 12:40-13:20 ***Oral presentations selected from submitted abstracts and/or Round table or controversial debates***

13:20-14:50 **Lunch**

13:50-14:50 **Possible slot for a SATELLITE SYMPOSIUM**

SESSION III – BIOLOGY 3

Chair: TBA

14:50-15:10	Epigenetics of lymphoid malignancies	Laura Pasqualucci (New York)
15:10-15:15	<i>Discussion</i>	
15:15-15:35	Epigenetics of lymphoid malignancies	Ari Melnick (New York)
15:35-15:40	<i>Discussion</i>	
15:40-16:00	DNA damage response in lymphoid malignancies	Christian Reinhardt (Cologne)
16:00-16:05	<i>Discussion</i>	
16:05-16:25	Splicing defects (SF3B1) in lymphoid malignancies	Omar Abdel Wahab (New York)
16:25-16:30	<i>Discussion</i>	
16:30-16:50	Cell cycle regulation	Selena Chen Kiang (New York)
16:50-16:55	<i>Discussion</i>	
16:55-17:25	<i>Oral presentations selected from submitted abstracts and/or Round table or controversial debates</i>	

17:25-17:55 **Coffee break**

**SESSION IV – IMPACT OF CURRENT AND FUTURE STRATEGIES ON REIMBURSEMENT POLICY.
DISPARITY OF CLL AND LYMPHOMA TREATMENT IN EUROPE AND THE WORLD**

Chair: TBA

17:55-18:15	TBA	Jackson Orem (Uganda)*
18:15-18:20	Discussion	
18:20-18:40	TBA	TBA
18:40-18:45	Discussion	
18:45-19:05	TBA	Speaker TBA
19:05-19:10	Discussion	
19:10-19:40	Round Table	

Saturday, September 16, 2017

08:00-09:30 **Possible slot for a SATELLITE SYMPOSIUM**

08:30-09:30 **3 Meet the Expert sessions**

09:30-09:45 **Coffee break**

SESSION V – BIOLOGY 4: MOLECULAR DIAGNOSTICS AND DISEASE ASSESSMENT IN LYMPHOMA

Chair: TBA

09:45-10:05	MRD in CLL	Andy Rawstron (Leeds)*
10:05-10:10	<i>Discussion</i>	

10:10-10:30	MRD, circulating tumour DNA in NHL	Ash Alizadeh (Palo Alto)
10:30-10:35	<i>Discussion</i>	
10:35-10:55	Diagnostic work up and genomics in CLL	Stephan Stilgenbauer (Ulm)
10:55-11:00	<i>Discussion</i>	
11:00-11:20	Initial diagnostic work up of MCL	Martin Dreyling (Munich)
11:20-11:25	<i>Discussion</i>	
11:25-11:45	Initial diagnostic work up of follicular lymphoma, others	TBA
11:45-11:50	<i>Discussion</i>	
11:50-13:00	Lunch	

SESSION VI – CELLULAR AND OTHER IMMUNOTHERAPIES FOR INDOLENT LYMPHOID MALIGNANCIES

Chair: TBA

13:00-13:20	CART in indolent NHL	Carl June (Philadelphia)
13:20-13:25	<i>Discussion</i>	
13:25-13:45	Novel bispecific antibodies	Ralf Bargou (Würzburg)
13:45-13:50	<i>Discussion</i>	
13:50-14:10	Status of allogeneic transplant immunotherapy	David Maloney (Seattle)
14:10-14:15	<i>Discussion</i>	
14:15-14:35	Checkpoint inhibitors	Stephen Ansell (Rochester)
14:35-14:40	<i>Discussion</i>	
14:40-15:00	Mechanisms of resistance to immunotherapies	Andrei Thomas-Tikhonenko (Philadelphia)
15:00-15:05	<i>Discussion</i>	
14:50-15:20	<i>Selected oral presentations and/or Round table or controversial debates</i>	
15:20-15:50	<i>Coffee Break</i>	

SESSION VII – UPDATE ON NOVEL AGENTS IN NHL

Chair: TBA

15:50-16:10	BCL2 & regulation of the apoptotic response in lymphoid malignancies	Antony Letai (Boston)
16:10-16:15	<i>Discussion</i>	
16:15-16:35	Regulation of Mcl1, BCL2 and other regulators of apoptosis as druggable targets	TBA
16:35-16:40	<i>Discussion</i>	
16:40-17:00	BCL2 inhibitors, up date on clinical development	Andrew W. Roberts (Parkville)
17:00-17:05	<i>Discussion</i>	
17:05-17:25	BTK inhibitors	TBA
17:25-17:30	<i>Discussion</i>	
17:30-17:50	PI3K inhibitors	Gilles Salles (Lyon)

17:50-17:55 *Discussion*

17:55-18:15 Open slot

18:15-18:20 *Discussion*

18:20-18:50 *Selected oral presentations and/or Round table or controversial debates*

19:00-20:30 *Manned Poster Session with refreshments*

Sunday, September 17, 2017

07:30-08:30 3 Simultaneous Meet the Expert Sessions

SESSION VIII – STATE OF THE ART TREATMENT AND STRATEGIES OF INTERNATIONAL STUDY GROUPS TO INTEGRATE GENOMICS, NOVEL AGENTS AND TRADITIONAL APPROACHES INTO ONE TREATMENT CONCEPT

Chair: TBA

08:45-09:05	Lysa	Gilles Salles (Lyon)
09:05-09:10	<i>Discussion</i>	
09:10-09:30	DCLLSG	Michael Hallek (Cologne)
09:30-09:35	<i>Discussion</i>	
09:35-09:55	GIMEMA - FIL	Robin Foà (Rome)
09:55-10:00	<i>Discussion</i>	
10:00-10:30	Coffee Break	
10:30-10:50	Indolent lymphoma trials in the US (ECOG)	Richard Little (Bethesda)
10:50-10:55	<i>Discussion</i>	
10:55-11:15	European Mantle Cell Network	Martin Dreyling (Munich)
11:15-11:20	<i>Discussion</i>	
11:20-11:40	UK National lymphoma group	Simon Rule (Plymouth)
11:40-11:45	<i>Discussion</i>	
11:45-12:15	<i>Round Table</i>	

MEETING CLOSURE

* Speakers pending confirmation